Agios Pharmaceuticalsincis A Biopharmaceutical Company Based In Cambridgemassachusettsfounded In 2007Agios Specializes In Developing Therapies That Target Cellular Metabolism For Cancer And Rare Genetic Diseasesthe Company Became Public In 2013 And Has Since Focused On Addressing Unmet Medical Needs Through Innovative Research Agios Has Several Fda Approved Therapiesincluding Idhifa For Acute Myeloid Leukemia With An Idh2 Mutationtibsovo For Idh1 Mutated Aml And Cholangiocarcinomaand Pyrukyndthe First Oral Treatment For Hemolytic Anemiasthe Company Is Dedicated To Small Molecule Therapeutics And Is Actively Working On Investigational Treatments For Conditions Such As Thalassemia And Sickle Cell Disease With A Workforce Of 712 Employees And A Commitment To Research And Developmentagios Collaborates With Industry Leaders To Enhance Its Impact In Oncology And Hematologythe Company Emphasizes A Patient Centric Approachaiming To Pioneer Advancements In Cellular Metabolism Science
